Percutaneous Coronary Intervention Clinical Trial
— PEBCBLOOfficial title:
Palpitate-Eluting Balloon Angioplasty in the Treatment of Coronary Bifurcation Lesion Evaluated by OCT
The aim of the study is to use optical coherence tomography (OCT) to investigate the efficacy of Paclitaxel-eluting PTCA-balloon dilation (SeQuent Please) in SB and drug eluting stent (EXCEL stent) deployment in the main branch (reference diameter: ≥ 2.5 mm and ≤ 4.0 mm, reference diameter of side branch: ≥ 2.0 mm and ≤ 3.5 mm, length of stenoses in either branch ≤ 30 mm) in the treatment of significant (>70%) de-novo-bifurcation stenoses of any Medina classification type in the native coronary artery as reflected by procedural success and to evaluate the preservation of vessel patency.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 2015 |
Est. primary completion date | January 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: Patient Inclusion Criteria - Inclusion Criteria: Patient Related - Patients with stable angina pectoris (CCS class 1-3) or with unstable angina pectoris (Braunwald class 1-2, A-C) or documented ischemia or with documented silent ischemia - Patients eligible for coronary revascularization by means of PCI - Patients must be 18 years of age - Women of childbearing potential may not be pregnant nor have the desire to becoming pregnant during the first year following the study procedure. Hence, patients will be advised to use an adequate birth control method up to and including 6-month follow-up - Patients who are mentally and linguistically able to understand the aim of the study and to show sufficient compliance in following the study protocol - Patients must agree to undergo the 9-month angiographic follow-up - Patients must agree to undergo the 3-year clinical follow-up - Patient is able to verbally acknowledge and understand the associated risks, benefits, and treatment alternatives of this trial. The patients, by providing their informed consent, must agree to these risks and benefits as stated in the patient informed consent document. Inclusion Criteria: Lesion Related - De-novo bifurcational native left coronary artery lesion (reference diameter LAD or LCx:2.5 mm-4.0 mm, length of stenosis: =30 mm, reference diameter D1/D2 or OMS1/OMS2:2.0 mm -3.5 mm, length of stenosis: =30 mm) - Diameter stenosis pre procedure must be either 70 % in either one or both branches of the lesion (i.e. bifurcational lesion of any type of the Medina classification) or 50 % if ischemia corresponding to the target lesion is documented either by exercise stress ECG, stress echocardiography, scintigraphy, MRT, or suspected based on angina pectoris - Single or multi-vessel coronary artery disease Exclusion Criteria: Patient Exclusion Criteria - Exclusion Criteria: Patient Related - Patients with acute (<24 h) or recent (48 hours) myocardial infarction - Patients with unstable angina pectoris (Braunwald class 3) - Patients with severe congestive heart failure - Patients with severe heart failure NYHA IV - Patients demonstrating clinical signs of cardiogenic shock at the time of the procedure (systolic blood pressure of less than 80 mmHg requiring inotropic support, IABP, and/or fluid challenge) - Patients with severe valvular heart disease - Women who are pregnant or lactating - Patients with life expectancy of less than five years or factors making clinical follow-up difficult - Patients with bleeding diathesis in whom anticoagulation or anti-platelet medication is contraindicated - Patients who had a cerebral stroke <6 months prior to the procedure - Patient participates in other clinical trials involving any investigational device or drug - Untreated hyperthyroidism - Patient has presence or history of severe renal failure (GFR<30ml/min, "Cockcroft Gault") and is therefore at high risk for angiography associated renal complications. Patient's serum creatinine levels must be documented - Post transplantation of any organ or immune suppressive medication - Other disease to jeopardize follow-up (e.g,malignancy) - Addiction to any drug or to alcohol - Patients with any type of surgery during the week preceding the interventional procedure. - Therapy with anticoagulants - After PTCA,Coronary artery dissection appears Exclusion Criteria: Lesion Related - Evidence of extensive thrombosis within target vessel before the intervention - Multilesion percutaneous coronary intervention beside the bifurcation lesion in the left coronary artery (no other intervention is admitted during the same procedure) - Patients with another coronary stent implanted previously into the target vessel =15 mm distant to the current lesion, drug eluting stents less than 9 months and bare metal stents or stents with passive coatings less than 3 months before the PEBCBLO - Target lesion located in any type of coronary bypass (i.e,venous graft, arterial bypass) or graft/native artery connection - Coronary artery occlusion of any type (e.g, acute or chronic) - In-stent restenosis - In-segment restenosis of the native vessel within 4 mm adjacent to the target lesion Exclusion Criteria Related to Concomitant Medication - Patient is intolerant to aspirin and/or the ADP-antagonists clopidogrel/ticlopidine or has a history of neutropenia, thrombocytopenia induced by ADP-antagonists, or severe hepatic dysfunction prohibiting the use of clopidogrel |
Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
China | The Second Hospital of Jilin University | Changchun | Jilin |
Lead Sponsor | Collaborator |
---|---|
Second Hospital of Jilin University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | In-segment late lumen loss | In-segment late lumen loss in the side branch and main branch evaluated by OCT | 9 months | No |
Secondary | major adverse cardiac events (MACE) | cardiac death, myocardial infarction and target lesion revascularization | 9 months | No |
Secondary | Procedural success | a stenosis =30% in the MB and =50% in the SB along with TIMI III flow | 10 minutes | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Not yet recruiting |
NCT05669222 -
The FAVOR V AMI Trial
|
N/A | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05240781 -
Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk
|
N/A | |
Recruiting |
NCT03378934 -
Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
|
Phase 4 | |
Not yet recruiting |
NCT06025071 -
Residual Inflammatory Risk-Guided colcHicine in Elderly Trial
|
Phase 4 | |
Withdrawn |
NCT04043091 -
Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction
|
N/A | |
Completed |
NCT02837744 -
Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure
|
||
Completed |
NCT03085823 -
The All-comers Sirolimus-coated Balloon European Registry
|
||
Completed |
NCT02044146 -
A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk
|
Phase 2/Phase 3 | |
Completed |
NCT03131271 -
Effect of Ice Bag Application to Femoral Region on Pain in Patients Undergoing Percutaneous Coronary Intervention
|
N/A | |
Completed |
NCT01156571 -
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
|
Phase 3 | |
Completed |
NCT01135667 -
Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI
|
Phase 4 | |
Unknown status |
NCT00751491 -
Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)
|
Phase 3 | |
Completed |
NCT00725868 -
Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention
|
N/A | |
Completed |
NCT03708588 -
Chewed Versus Integral Pill of Ticagrelor
|
Phase 4 | |
Completed |
NCT04163393 -
R-One Efficiency For PCI Evolution With Robotic Assistance
|
N/A | |
Recruiting |
NCT05554588 -
Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI
|
N/A | |
Recruiting |
NCT06080919 -
Plaque Modification And Impact On Microcirculatory Territory After Drug-Coated Balloon Percutaneous Coronary Intervention (PLAMI).
|
N/A | |
Recruiting |
NCT05353140 -
LAAO Versus NOAC in Patients With AF and PCI
|
N/A |